No wonder metabolic syndrome is called syndrome X. Instead of being recognized as a separate disease, it is considered a constellation of many conditions. "The biggest problem is a failure to address the underlying problem—insulin resistance," says Robert Epstein, MD, chief medical officer for Medco Health Solutions in Franklin Lakes, N.J. He calls metabolic syndrome one of the country's top five health problems.
Patients with metabolic syndrome have three or more of the following risk factors: excessive abdominal fat, low amounts of HDL, elevated triglyceride levels, high blood pressure and abnormal blood sugar. They are at three-and-a-half times greater risk of death from coronary heart disease and have increased risk for liver and kidney disease.
Although the prevalence of metabolic syndrome increases with age, it is present in as many as 5% of elementary school children, according to Family Practice News, which reported the results of a study presented in July at the annual meeting of the American College of Sports Medicine.
"Is there a problem called 'metabolic syndrome?'" asks Michael Fleming, MD, past president of the American Academy of Family Physicians and a practicing family physician in Shreveport, La. "It's academic. Metabolic syndrome is an amalgamation of diseases that begs for treatment by a primary care physician. It doesn't make sense to be treated by different physicians for each problem."
To David Katz, MD, director of the Prevention Research Center, Yale School of Medicine, metabolic syndrome is not viewed as a disease but rather, it is considered a precursor to diabetes. "By using metabolic syndrome as an indicator for diabetes, we can pull back patients from the brink by addressing obesity-the root cause of metabolic syndrome-and identifying treatable cardiovascular conditions," he says.
In August, the American Diabetes Assn. and the European Association for the Study of Diabetes issued a joint statement, saying that "metabolic syndrome" was poorly defined, inconsistently used and in need of further research. The president of the European diabetes association says that there is "no combination of risk factors that boost a person's cardiovascular risk beyond the sum of its parts, or constitutes a separate disease."
A paper published in the September issue of Diabetes Care and Diabetologia warned doctors that they should not diagnose people with the syndrome or treat it as a separate condition until the science behind it is clear.
In response, the American Heart Assn. (AHA) and the National Heart, Lung and Blood Institute (NHLBI) issued a statement, saying that metabolic syndrome consists of multiple, interrelated risk factors that increase the risk of cardiovascular disease by one-and-a-half to three times, raise the risk of diabetes 2 three to five times and affect more than 26 million adults in the United States.
Although the two organizations confirmed the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines, they did some tweaking: fasting glucose drops from equal to or greater than 110 milligrams per deciliter to 100; triglycerides greater than or equal to 400 milligrams per deciliter, if not fasting, and glucose greater than or equal to 140 milligrams per deciliter two hours after eating have been added; and less emphasis has been placed on waist circumference. A joint AHA/NHLBI panel states that an increased waist circumference serves as an effective diagnostic tool, but it is not necessary for the diagnosis of metabolic syndrome if other criteria are present. The panel also says that some persons who are not obese by traditional measures, may still be insulin resistant and have other metabolic risk factors.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More